Form 4 for LLY Lilly (Eli)
Accepted 2024-02-14 00:00:00 ET · period of report 2024-02-12 · accession 0000059478-24-000050 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-02-14 | 2024-02-12 | LLY | Hakim Anat | EVP, GC, Sec | A - Grant | $737.26 | +5,815 | 30.5K | +24% | +$4.29M |
| D | 2024-02-14 | 2024-02-12 | LLY | Hakim Anat | EVP, GC, Sec | A - Grant | $0.00 | +4,904 | 4,904 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-12 | A | A | 5,815 | $737.26 | 30,479 | D | — | — | |
| 2 | Derivative | Restricted Stock Unit | 2024-02-12 | A | A | 4,904 | $0.00 | 4,904 | D | — · 2025-02-01 to 2025-02-01 | 4,904 Common Stock | (F1) Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. |